Hyloris announces approval of novel drug for post-operation pain management

BELGIUM – Hyloris Pharmaceuticals SA, a specialty biopharmaceutical company dedicated to addressing unmet medical needs by reinventing existing medications, has announced the expansion of the European footprint of Maxigesic IV to treat post-operative pain in the UK. Hyloris Pharmaceuticals has a diverse pipeline of 13 reformulated and repurposed value-added medicines that have the potential to outperform existing medications. In addition, the company is developing and registering three high barrier generic products. Two products are currently in the early stages of commercialization with partners: Sotalol IV for atrial fibrillation treatment and…

Read More

Boehringer launches state-of-the-art biopharma production facility in Vienna

GERMANY – German family-owned biopharma major Boehringer Ingelheim has inaugurated a state-of-the-art biologics facility in Vienna, Austria heralding the single-largest investment in the company’s history. The Large-Scale Cell Culture (LSCC) is one of the most advanced in its own league, boasting a high degree of digitalization and automation through smart technologies and artificial intelligence (AI) applications. The facility boasts a total of 48 stainless-steel bioreactors at various scales, boasts a production capacity of 185,000 liters, exceeding its original planned capacity of 150,000 liters. The facility, which increased mammalian large scale…

Read More